Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. [Trial of device that is not approved or cleared by the U.S. FDA]

   Withheld

   NCT07340684 · Neurent Medical Limited · 0 U.S. investigators

   $34,094research payments

2. Esophageal Protection Study: A Multicenter Study

   Completed · Not applicable · AF - Atrial Fibrillation

   NCT04577859 · Haemonetics Corporation · 3 U.S. investigators

   $33,929research payments

3. Intra-operative Pancreatoscopy in Patients With IPMN

   Active, not recruiting · Intraductal Papillary Mucinous Neoplasm

   NCT03729453 · Boston Scientific Corporation · 3 U.S. investigators

   $33,777research payments

4. Baroreflex Activation Therapy for Heart Failure

   Completed · Not applicable · Heart Failure

   NCT02627196 · Cvrx, Inc. · 1 U.S. investigator

   $33,665research payments

5. A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

   Completed · Phase 3 · Seasonal Influenza

   NCT05566639 · ModernaTX, Inc. · 5 U.S. investigators

   $33,087research payments

6. A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

   Recruiting · Phase 1 · Advanced or Metastatic Adrenocortical Carcinoma

   NCT07189403 · Daiichi Sankyo Inc. · 1 U.S. investigator

   $33,000research payments

7. NEUROMARK Registry Study

   Active, not recruiting · Not applicable · Chronic Rhinitis

   NCT05937308 · Neurent Medical Limited · 0 U.S. investigators

   $32,899research payments

8. Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

   Terminated · Phase 1, Phase 2 · Metastatic Neoplasm

   NCT04418661 · Sanofi US Services Inc. · 1 U.S. investigator

   $32,852research payments

9. Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

   Completed · Phase 3 · Schizophrenia

   NCT03238326 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 10 U.S. investigators

   $32,834research payments

10. A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

    Recruiting · Phase 3 · Acne Scars

    NCT07207369 · AbbVie Inc. · 4 U.S. investigators

    $32,789research payments

11. A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

    Completed · Phase 3 · Type 2 Diabetes

    NCT05275400 · Eli Lilly and Company · 11 U.S. investigators

    $32,627research payments

12. Neuroblastoma Maintenance Therapy Trial

    Active, not recruiting · Phase 2 · Neuroblastoma

    NCT02679144 · Uswm, LLC · 1 U.S. investigator

    $32,600research payments

13. Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

    Recruiting · Phase 2 · Ventral Hernia

    NCT07226791 · AbbVie Inc. · 3 U.S. investigators

    $32,500research payments

14. A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

    Completed · Phase 1 · Hepatic Function Abnormal

    NCT05718258 · Genzyme Corporation · 1 U.S. investigator

    $32,199research payments

15. Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

    Completed · Phase 1 · Melanoma

    NCT02680184 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $31,902research payments

16. The PEERLESS Study

    Completed · Not applicable · Pulmonary Embolism

    NCT05111613 · Stryker Corporation · 5 U.S. investigators

    $31,433research payments

17. A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteer

    NCT06698926 · AbbVie Inc. · 0 U.S. investigators

    $31,380research payments

18. A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

    Completed · Phase 1 · Healthy Volunteer

    NCT06673238 · AbbVie Inc. · 0 U.S. investigators

    $30,420research payments

19. A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

    Completed · Phase 3 · Psoriatic Arthritis

    NCT03104374 · AbbVie Inc. · 2 U.S. investigators

    $30,394research payments

20. Evaluation of Dupilumab in Children With Uncontrolled Asthma

    Completed · Phase 3 · Asthma

    NCT02948959 · Genzyme Corporation · 0 U.S. investigators

    $30,250research payments

21. Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

    Recruiting · Phase 1, Phase 2 · Ischemia Reperfusion Injury

    NCT04005469 · United Therapeutics Corporation · 1 U.S. investigator

    $30,196research payments

22. Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

    Completed · Phase 3 · Chronic Spontaneous Urticaria

    NCT04180488 · Genzyme Corporation · 4 U.S. investigators

    $30,125research payments

23. BPH Global Registry

    Recruiting · Benign Prostatic Hyperplasia

    NCT05543200 · Teleflex LLC · 1 U.S. investigator

    $30,000research payments

24. NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

    Recruiting · Phase 2 · Borderline Resectable Pancreatic Ductal Adenocarcinoma

    NCT06821997 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $29,890research payments

25. Connect® MM- The Multiple Myeloma Disease Registry

    Terminated · Multiple Myeloma

    NCT01081028 · E.r. Squibb & Sons, L.l.c. · 13 U.S. investigators

    $29,711research payments

26. A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

    Completed · Phase 2 · Hormone Receptor Positive Breast Cancer

    NCT02675231 · Eli Lilly and Company · 2 U.S. investigators

    $29,308research payments

27. A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

    Completed · Phase 1, Phase 2 · Duchenne Muscular Dystrophy

    NCT03375164 · Sarepta Therapeutics, Inc. · 0 U.S. investigators

    $29,175research payments

28. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    Recruiting · Phase 3 · Alzheimer's Disease

    NCT06976203 · E.r. Squibb & Sons, L.l.c. · 19 U.S. investigators

    $29,116research payments

29. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumor

    NCT06997029 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

    $29,063research payments

30. Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Active, not recruiting · Phase 2 · Leukemia

    NCT05479994 · Beone Medicines Ltd. · 2 U.S. investigators

    $27,820research payments

31. A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

    Completed · Phase 1 · Acute Myeloid Leukemia (AML)

    NCT03625505 · AbbVie Inc. · 1 U.S. investigator

    $27,592research payments

32. A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

    Recruiting · Phase 2 · Chronic Graft Versus Host Disease

    NCT07116031 · Sanofi US Services Inc. · 1 U.S. investigator

    $27,392research payments

33. Benefits of Bimodal Streaming With MED-EL Cochlear Implants and Starkey Hearing Aids

    Completed · Not applicable · Hearing Loss, Sensorineural

    NCT07028619 · Med-el Corporation · 2 U.S. investigators

    $27,369research payments

34. A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

    Terminated · Phase 2 · Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

    NCT04875975 · UCB SA · 2 U.S. investigators

    $27,362research payments

35. Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

    Terminated · Phase 1 · Solid Tumor

    NCT05494762 · Beigene, Ltd. · 2 U.S. investigators

    $27,185research payments

36. Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Terminated · Phase 1 · Multiple Myeloma

    NCT04570631 · AbbVie Inc. · 2 U.S. investigators

    $27,126research payments

37. A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

    Completed · Phase 1 · Myelodysplastic Syndromes (MDS)

    NCT02942290 · AbbVie Inc. · 7 U.S. investigators

    $27,079research payments

38. Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

    Recruiting · Phase 2 · Colorectal Carcinoma Metastatic in the Liver

    NCT06555133 · Sirtex Medical Inc · 1 U.S. investigator

    $27,039research payments

39. A Drug-drug Interaction Study of Avapritinib and Midazolam

    Completed · Phase 1 · Gastrointestinal Stromal Tumors

    NCT04908176 · Blueprint Medicines Corporation · 2 U.S. investigators

    $26,986research payments

40. Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    Recruiting · Phase 2, Phase 3 · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

    NCT03013998 · Sumitomo Pharma America, Inc. · 1 U.S. investigator

    $26,963research payments

41. Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

    Completed · Phase 3 · Psoriasis

    NCT04713592 · AbbVie Inc. · 2 U.S. investigators

    $26,903research payments

42. An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

    Completed · Phase 4 · Renal Cell Carcinoma

    NCT02596035 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $26,880research payments

43. Starling Registry Study

    Completed · Hemodynamic Monitoring

    NCT04648293 · Baxter Healthcare · 1 U.S. investigator

    $26,417research payments

44. A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

    Completed · Phase 4 · Inflammatory Bowel Disease

    NCT06346288 · AbbVie Inc. · 2 U.S. investigators

    $26,304research payments

45. Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

    Active, not recruiting · Retinopathy of Prematurity

    NCT04515524 · Regeneron Pharmaceuticals, Inc. · 7 U.S. investigators

    $26,206research payments

46. A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

    Recruiting · Niemann-Pick Diseases

    NCT06192576 · Sanofi US Services Inc. · 3 U.S. investigators

    $26,123research payments

47. Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)

    Active, not recruiting · Not applicable · Acute Respiratory Infection

    NCT06271655 · Biomerieux Inc · 1 U.S. investigator

    $25,995research payments

48. The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

    Active, not recruiting · Not applicable · Venous Thromboses

    NCT05409976 · W. L. Gore & Associates, Inc. · 2 U.S. investigators

    $25,941research payments

49. LOWER: Lomitapide Observational Worldwide Evaluation Registry

    Completed · Homozygous Familial Hypercholesterolemia

    NCT02135705 · Chiesi USA, Inc. · 16 U.S. investigators

    $25,902research payments

50. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    Recruiting · Phase 1, Phase 2 · Breast Cancer

    NCT05768139 · Eli Lilly and Company · 1 U.S. investigator

    $25,864research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.